{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:06:55Z","timestamp":1791259615024,"version":"4.1.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Pfizer Italy"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Duchenne Muscular Dystrophy (DMD) is an X-linked recessive neuromuscular disorder primarily affecting males, caused by mutations in the dystrophin gene. The absence of dystrophin protein leads to progressive skeletal muscle degeneration. Recent advances in the therapeutic landscape underscore the need to identify appropriate outcome measures to assess treatment efficacy in ambulant and non-ambulant DMD patients, across clinical and research settings. This is essential for accurately evaluating new treatments and attributing therapeutic benefits.<\/jats:p>\n          <jats:p>It is crucial to establish a robust correlation between outcome scores and disease progression patterns. This task is challenging since functional test performance may be influenced by different patient\u2019s characteristics, including the physiological evolution of the neurodevelopment together with the disease progression. While widely used DMD outcomes such as the North Star Ambulatory Assessment, the 6-Minute Walking Test, the 4 stairs climbed, and the Performance of the Upper Limb exhibit reliability and validity, their clinical significance is influenced by the wide phenotype and progression variability of the disease.<\/jats:p>\n          <jats:p>We present and discuss the features (relevance, quantifiability, validity, objectivity, reliability, sensitivity, specificity, precision) of available DMD outcome measures, including new potential measures that may be provided by digital tools and artificial intelligence.<\/jats:p>","DOI":"10.1007\/s13760-024-02600-2","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T01:01:36Z","timestamp":1722387696000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["\u201cIf you cannot measure it, you cannot improve it\u201d. Outcome measures in Duchenne Muscular Dystrophy: current and future perspectives"],"prefix":"10.1007","volume":"125","author":[{"given":"Silvia","family":"Benemei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Boni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marika","family":"Pane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"issue":"1","key":"2600_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","volume":"7","author":"D Duan","year":"2021","unstructured":"Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A (2021) Duchenne muscular dystrophy. Nat Rev Dis Primers 7(1):13. https:\/\/doi.org\/10.1038\/s41572-021-00248-3","journal-title":"Nat Rev Dis Primers"},{"issue":"9152","key":"2600_CR2","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/s0140-6736(98)05279-9","volume":"353","author":"KM Bushby","year":"1999","unstructured":"Bushby KM, Hill A, Steele JG (1999) Failure of early diagnosis in symptomatic duchenne muscular dystrophy. Lancet 353(9152):557\u2013558. https:\/\/doi.org\/10.1016\/s0140-6736(98)05279-9","journal-title":"Lancet"},{"issue":"1","key":"2600_CR3","doi-asserted-by":"publisher","first-page":"90","DOI":"10.33590\/emj\/10311993","volume":"2","author":"H Van Ruiten","year":"2017","unstructured":"Van Ruiten H, Bushby K, Guglieri M (2017) State-Of-The-art advances in Duchenne muscular dystrophy. Eur Med J 2(1):90\u201399. https:\/\/doi.org\/10.33590\/emj\/10311993","journal-title":"Eur Med J"},{"issue":"5","key":"2600_CR4","doi-asserted-by":"publisher","first-page":"CD003725","DOI":"10.1002\/14651858.CD003725.pub4","volume":"2016","author":"E Matthews","year":"2016","unstructured":"Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur AY (2016) Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst Rev 2016(5):CD003725. https:\/\/doi.org\/10.1002\/14651858.CD003725.pub4","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"2600_CR5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S2213-2600(21)00581-6","volume":"10","author":"DJ Birnkrant","year":"2022","unstructured":"Birnkrant DJ, Bello L, Butterfield RJ, Carter JC, Cripe LH, Cripe TP et al (2022) Cardiorespiratory management of Duchenne muscular dystrophy: emerging therapies, neuromuscular genetics, and new clinical challenges. Lancet Respir Med 10(4):403\u2013420. https:\/\/doi.org\/10.1016\/S2213-2600(21)00581-6","journal-title":"Lancet Respir Med"},{"key":"2600_CR6","doi-asserted-by":"publisher","first-page":"359","DOI":"10.14744\/DAJPNS.2019.00052","volume":"32","author":"U Ozer","year":"2019","unstructured":"Ozer U, Tufan A (2019) Psychiatric comorbidities in cases with Duchenne muscular dystrophy: a case series. Dusunen Adam J Psychiatry Neurol Sci 32:359\u2013364. https:\/\/doi.org\/10.14744\/DAJPNS.2019.00052","journal-title":"Dusunen Adam J Psychiatry Neurol Sci"},{"issue":"4","key":"2600_CR7","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.jpeds.2012.03.020","volume":"161","author":"M Pane","year":"2012","unstructured":"Pane M, Lombardo ME, Alfieri P, D\u2019Amico A, Bianco F, Vasco G et al (2012) Attention deficit hyperactivity disorder and cognitive function in Duchenne muscular dystrophy: phenotype-genotype correlation. J Pediatr 161(4):705\u20139e1. https:\/\/doi.org\/10.1016\/j.jpeds.2012.03.020","journal-title":"J Pediatr"},{"key":"2600_CR8","doi-asserted-by":"publisher","unstructured":"Wasilewska E, Malgorzewicz S, Sobierajska-Rek A, Jablonska-Brudlo J, Gorska L, Sledzinska K et al (2020) Transition from Childhood to Adulthood in patients with Duchenne muscular dystrophy. Med (Kaunas) 56(9). https:\/\/doi.org\/10.3390\/medicina56090426","DOI":"10.3390\/medicina56090426"},{"key":"2600_CR9","doi-asserted-by":"publisher","unstructured":"Paramsothy PPDMPH, Herron Ar PhD MA, Lamb MMP, Kinnett K, Msn A, Wolff JP, Yang MM et al (2018) Health Care Transition experiences of males with childhood-onset Duchenne and Becker muscular dystrophy: findings from the Muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet) Health Care transitions and other Life experiences Survey. PLoS Curr 10. https:\/\/doi.org\/10.1371\/currents.md.7de8a1c6798d7a48d38ea09bd624e1cd","DOI":"10.1371\/currents.md.7de8a1c6798d7a48d38ea09bd624e1cd"},{"issue":"23","key":"2600_CR10","doi-asserted-by":"publisher","first-page":"e2304","DOI":"10.1212\/WNL.0000000000012910","volume":"97","author":"J Broomfield","year":"2021","unstructured":"Broomfield J, Hill M, Guglieri M, Crowther M, Abrams K (2021) Life Expectancy in Duchenne muscular dystrophy: reproduced individual Patient Data Meta-analysis. Neurology 97(23):e2304\u2013e14. https:\/\/doi.org\/10.1212\/WNL.0000000000012910","journal-title":"Neurology"},{"key":"2600_CR11","unstructured":"FDA Duchenne Muscular Dystrophy and Related Dystrophinopathies: Developing Drugs for Treatment 2018 [ https:\/\/www.fda.gov\/media\/92233\/download"},{"issue":"4","key":"2600_CR12","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3233\/JND-170280","volume":"4","author":"Z Koeks","year":"2017","unstructured":"Koeks Z, Bladen CL, Salgado D, Zwet E, Pogoryelova O, McMacken G et al (2017) Clinical outcomes in Duchenne muscular dystrophy: a study of 5345 patients from the TREAT-NMD DMD Global Database. J Neuromuscul Dis 4(4):293\u2013306. https:\/\/doi.org\/10.3233\/JND-170280","journal-title":"J Neuromuscul Dis"},{"issue":"1","key":"2600_CR13","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13063-017-1870-2","volume":"18","author":"C Heneghan","year":"2017","unstructured":"Heneghan C, Goldacre B, Mahtani KR (2017) Why clinical trial outcomes fail to translate into benefits for patients. Trials 18(1):122. https:\/\/doi.org\/10.1186\/s13063-017-1870-2","journal-title":"Trials"},{"issue":"2","key":"2600_CR14","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1191\/1740774505cn078oa","volume":"2","author":"S Piantadosi","year":"2005","unstructured":"Piantadosi S (2005) Translational clinical trials: an entropy-based approach to sample size. Clin Trials 2(2):182\u2013192. https:\/\/doi.org\/10.1191\/1740774505cn078oa","journal-title":"Clin Trials"},{"issue":"9","key":"2600_CR15","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.4155\/cli.11.113","volume":"1","author":"K Bushby","year":"2011","unstructured":"Bushby K, Connor E (2011) Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings. Clin Investig (Lond) 1(9):1217\u20131235. https:\/\/doi.org\/10.4155\/cli.11.113","journal-title":"Clin Investig (Lond)"},{"issue":"4","key":"2600_CR16","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s00246-021-02797-6","volume":"43","author":"KE Gambetta","year":"2022","unstructured":"Gambetta KE, McCulloch MA, Lal AK, Knecht K, Butts RJ, Villa CR et al (2022) Diversity of Dystrophin Gene mutations and Disease Progression in a contemporary cohort of Duchenne muscular dystrophy. Pediatr Cardiol 43(4):855\u2013867. https:\/\/doi.org\/10.1007\/s00246-021-02797-6","journal-title":"Pediatr Cardiol"},{"issue":"4","key":"2600_CR17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1212\/WNL.0000000000002891","volume":"87","author":"L Bello","year":"2016","unstructured":"Bello L, Morgenroth LP, Gordish-Dressman H, Hoffman EP, McDonald CM, Cirak S et al (2016) DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study. Neurology 87(4):401\u2013409. https:\/\/doi.org\/10.1212\/WNL.0000000000002891","journal-title":"Neurology"},{"issue":"3","key":"2600_CR18","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D et al (2018) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol 17(3):251\u2013267. https:\/\/doi.org\/10.1016\/S1474-4422(18)30024-3","journal-title":"Lancet Neurol"},{"issue":"1","key":"2600_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13023-021-01758-9","volume":"16","author":"S Kourakis","year":"2021","unstructured":"Kourakis S, Timpani CA, Campelj DG, Hafner P, Gueven N, Fischer D et al (2021) Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: can we do better? Orphanet J Rare Dis 16(1):117. https:\/\/doi.org\/10.1186\/s13023-021-01758-9","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2600_CR20","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s13023-021-01837-x","volume":"16","author":"S Zhang","year":"2021","unstructured":"Zhang S, Qin D, Wu L, Li M, Song L, Wei C et al (2021) Genotype characterization and delayed loss of ambulation by glucocorticoids in a large cohort of patients with Duchenne muscular dystrophy. Orphanet J Rare Dis 16(1):188. https:\/\/doi.org\/10.1186\/s13023-021-01837-x","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"2600_CR21","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1002\/acn3.51046","volume":"7","author":"L Bello","year":"2020","unstructured":"Bello L, D\u2019Angelo G, Villa M, Fusto A, Vianello S, Merlo B et al (2020) Genetic modifiers of respiratory function in Duchenne muscular dystrophy. Ann Clin Transl Neurol 7(5):786\u2013798. https:\/\/doi.org\/10.1002\/acn3.51046","journal-title":"Ann Clin Transl Neurol"},{"issue":"15","key":"2600_CR22","doi-asserted-by":"publisher","first-page":"e1540","DOI":"10.1212\/WNL.0000000000201626","volume":"100","author":"F Muntoni","year":"2023","unstructured":"Muntoni F, Signorovitch J, Sajeev G, Lane H, Jenkins M, Dieye I et al (2023) DMD genotypes and motor function in Duchenne muscular dystrophy: a multi-institution Meta-analysis with implications for clinical trials. Neurology 100(15):e1540\u2013e54. https:\/\/doi.org\/10.1212\/WNL.0000000000201626","journal-title":"Neurology"},{"issue":"9","key":"2600_CR23","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.nmd.2016.05.016","volume":"26","author":"E Mercuri","year":"2016","unstructured":"Mercuri E, Signorovitch JE, Swallow E, Song J, Ward SJ, Group DMDI et al (2016) Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy. Neuromuscul Disord 26(9):576\u2013583. https:\/\/doi.org\/10.1016\/j.nmd.2016.05.016","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"2600_CR24","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/ppul.25111","volume":"56","author":"DJ Birnkrant","year":"2021","unstructured":"Birnkrant DJ, Carter JC (2021) Cardiopulmonary phenotypic variability and discordance in Duchenne muscular dystrophy: implications for new therapies. Pediatr Pulmonol 56(4):738\u2013746. https:\/\/doi.org\/10.1002\/ppul.25111","journal-title":"Pediatr Pulmonol"},{"issue":"11","key":"2600_CR25","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1093\/ptj\/pzaa140","volume":"100","author":"CR Senesac","year":"2020","unstructured":"Senesac CR, Barnard AM, Lott DJ, Nair KS, Harrington AT, Willcocks RJ et al (2020) Magnetic Resonance Imaging Studies in Duchenne muscular dystrophy: linking findings to the physical therapy clinic. Phys Ther 100(11):2035\u20132048. https:\/\/doi.org\/10.1093\/ptj\/pzaa140","journal-title":"Phys Ther"},{"issue":"10","key":"2600_CR26","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3390\/children8100835","volume":"8","author":"KD Mathews","year":"2021","unstructured":"Mathews KD, Conway KM, Gedlinske AM, Johnson N, Street N, Butterfield RJ et al (2021) Characteristics of clinical trial participants with Duchenne muscular dystrophy: data from the muscular dystrophy surveillance, Tracking, and Research Network (MD STARnet). Child (Basel) 8(10):835. https:\/\/doi.org\/10.3390\/children8100835","journal-title":"Child (Basel)"},{"issue":"4","key":"2600_CR27","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A et al (2018) Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol 17(4):347\u2013361. https:\/\/doi.org\/10.1016\/S1474-4422(18)30025-5","journal-title":"Lancet Neurol"},{"issue":"5","key":"2600_CR28","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S1474-4422(18)30026-7","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Colvin MK et al (2018) Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Lancet Neurol 17(5):445\u2013455. https:\/\/doi.org\/10.1016\/S1474-4422(18)30026-7","journal-title":"Lancet Neurol"},{"key":"2600_CR29","doi-asserted-by":"publisher","DOI":"10.3233\/JND-221666","author":"F Fortunato","year":"2023","unstructured":"Fortunato F, Ferlini A (2023) Biomarkers in Duchenne muscular dystrophy: current status and future directions. J Neuromuscul Dis. https:\/\/doi.org\/10.3233\/JND-221666","journal-title":"J Neuromuscul Dis"},{"key":"2600_CR30","unstructured":"Group F-NBW (2016-) BEST (biomarkers, EndpointS, and other tools) resource [Internet]. Bethesda (MD): National Institutes of Health (US): Silver Spring (MD). Food and Drug Administration (US)"},{"key":"2600_CR31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1067\/mcp.2001","volume":"69","author":"BDW Group","year":"2001","unstructured":"Group BDW (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89\u201395. https:\/\/doi.org\/10.1067\/mcp.2001","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"2600_CR32","doi-asserted-by":"publisher","first-page":"12167","DOI":"10.1038\/s41598-019-48548-9","volume":"9","author":"Y Hathout","year":"2019","unstructured":"Hathout Y, Liang C, Ogundele M, Xu G, Tawalbeh SM, Dang UJ et al (2019) Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne muscular dystrophy. Sci Rep 9(1):12167. https:\/\/doi.org\/10.1038\/s41598-019-48548-9","journal-title":"Sci Rep"},{"issue":"9\u201310","key":"2600_CR33","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1089\/hum.2022.190","volume":"34","author":"JS Chamberlain","year":"2023","unstructured":"Chamberlain JS, Robb M, Braun S, Brown KJ, Danos O, Ganot A et al (2023) Microdystrophin expression as a surrogate endpoint for Duchenne muscular dystrophy clinical trials. Hum Gene Ther 34(9\u201310):404\u2013415. https:\/\/doi.org\/10.1089\/hum.2022.190","journal-title":"Hum Gene Ther"},{"issue":"10","key":"2600_CR34","doi-asserted-by":"publisher","first-page":"761","DOI":"10.2217\/bmm-2020-0801","volume":"15","author":"SP Sherlock","year":"2021","unstructured":"Sherlock SP, Zhang Y, Binks M, Marraffino S (2021) Quantitative muscle MRI biomarkers in Duchenne muscular dystrophy: cross-sectional correlations with age and functional tests. Biomark Med 15(10):761\u2013773. https:\/\/doi.org\/10.2217\/bmm-2020-0801","journal-title":"Biomark Med"},{"issue":"2","key":"2600_CR35","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/pri.520","volume":"17","author":"E Scott","year":"2012","unstructured":"Scott E, Eagle M, Mayhew A, Freeman J, Main M, Sheehan J et al (2012) Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy. Physiother Res Int 17(2):101\u2013109. https:\/\/doi.org\/10.1002\/pri.520","journal-title":"Physiother Res Int"},{"issue":"6","key":"2600_CR36","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1002\/mus.21808","volume":"42","author":"CM McDonald","year":"2010","unstructured":"McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, Atkinson L et al (2010) The 6-minute walk test in Duchenne\/Becker muscular dystrophy: longitudinal observations. Muscle Nerve 42(6):966\u2013974. https:\/\/doi.org\/10.1002\/mus.21808","journal-title":"Muscle Nerve"},{"issue":"7","key":"2600_CR37","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/ptj\/pzx039","volume":"97","author":"M Ni","year":"2017","unstructured":"Ni M, Brown LG, Lawler D, Bean JF (2017) Reliability, validity, and minimal detectable change of four-step stair climb Power Test in Community-Dwelling older adults. Phys Ther 97(7):767\u2013773. https:\/\/doi.org\/10.1093\/ptj\/pzx039","journal-title":"Phys Ther"},{"issue":"11","key":"2600_CR38","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1111\/dmcn.12213","volume":"55","author":"A Mayhew","year":"2013","unstructured":"Mayhew A, Mazzone ES, Eagle M, Duong T, Ash M, Decostre V et al (2013) Development of the performance of the Upper Limb module for Duchenne muscular dystrophy. Dev Med Child Neurol 55(11):1038\u20131045. https:\/\/doi.org\/10.1111\/dmcn.12213","journal-title":"Dev Med Child Neurol"},{"issue":"1","key":"2600_CR39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/17518423.2022.2143924","volume":"26","author":"E Aldirmaz","year":"2023","unstructured":"Aldirmaz E, U\u011fur F, Yilmaz \u00d6, Karaduman A, Alemdaro\u011flu-G\u00fcrb\u00fcz \u0130 (2023) A New Instrument to assess dynamic balance in children with Duchenne muscular dystrophy: four Square Step Test and its validity, reliability and feasibility. Dev Neurorehabil 26(1):27\u201336. https:\/\/doi.org\/10.1080\/17518423.2022.2143924","journal-title":"Dev Neurorehabil"},{"key":"2600_CR40","unstructured":"EMA Guideline on the clinical investigation of medicinal products for the treatment of Duchenne and Becker muscular dystrophy 2016 [ https:\/\/bit.ly\/3S3JsXU"},{"issue":"7","key":"2600_CR41","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.nmd.2009.06.368","volume":"19","author":"ES Mazzone","year":"2009","unstructured":"Mazzone ES, Messina S, Vasco G, Main M, Eagle M, D\u2019Amico A et al (2009) Reliability of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscul Disord 19(7):458\u2013461. https:\/\/doi.org\/10.1016\/j.nmd.2009.06.368","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"2600_CR42","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.nmd.2022.02.009","volume":"32","author":"F Muntoni","year":"2022","unstructured":"Muntoni F, Signorovitch J, Sajeev G, Goemans N, Wong B, Tian C et al (2022) Real-world and natural history data for drug evaluation in Duchenne muscular dystrophy: suitability of the North Star Ambulatory Assessment for comparisons with external controls. Neuromuscul Disord 32(4):271\u2013283. https:\/\/doi.org\/10.1016\/j.nmd.2022.02.009","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"2600_CR43","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/mus.23905","volume":"48","author":"CM McDonald","year":"2013","unstructured":"McDonald CM, Henricson EK, Abresch RT, Florence J, Eagle M, Gappmaier E et al (2013) The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve 48(3):357\u2013368. https:\/\/doi.org\/10.1002\/mus.23905","journal-title":"Muscle Nerve"},{"issue":"6","key":"2600_CR44","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.nmd.2020.05.002","volume":"30","author":"KR Wagner","year":"2020","unstructured":"Wagner KR, Abdel-Hamid HZ, Mah JK, Campbell C, Guglieri M, Muntoni F et al (2020) Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy. Neuromuscul Disord 30(6):492\u2013502. https:\/\/doi.org\/10.1016\/j.nmd.2020.05.002","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"2600_CR45","first-page":"4","volume":"23","author":"DC Schorling","year":"2023","unstructured":"Schorling DC, Rawer R, Kuhlmann I, Muller C, Pechmann A, Kirschner J (2023) Mechanographic analysis of the timed 4 stair climb test - methodology and reference data of healthy children and adolescents. J Musculoskelet Neuronal Interact 23(1):4\u201325","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"10101","key":"2600_CR46","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","volume":"390","author":"CM McDonald","year":"2017","unstructured":"McDonald CM, Campbell C, Torricelli RE, Finkel RS, Flanigan KM, Goemans N et al (2017) Ataluren in patients with nonsense mutation duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390(10101):1489\u20131498. https:\/\/doi.org\/10.1016\/S0140-6736(17)31611-2","journal-title":"Lancet"},{"issue":"10","key":"2600_CR47","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.nmd.2015.07.009","volume":"25","author":"M Pane","year":"2015","unstructured":"Pane M, Fanelli L, Mazzone ES, Olivieri G, D\u2019Amico A, Messina S et al (2015) Benefits of glucocorticoids in non-ambulant boys\/men with Duchenne muscular dystrophy: a multicentric longitudinal study using the performance of Upper Limb test. Neuromuscul Disord 25(10):749\u2013753. https:\/\/doi.org\/10.1016\/j.nmd.2015.07.009","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"2600_CR48","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.nmd.2013.11.014","volume":"24","author":"M Pane","year":"2014","unstructured":"Pane M, Mazzone ES, Fanelli L, De Sanctis R, Bianco F, Sivo S et al (2014) Reliability of the performance of Upper Limb assessment in Duchenne muscular dystrophy. Neuromuscul Disord 24(3):201\u2013206. https:\/\/doi.org\/10.1016\/j.nmd.2013.11.014","journal-title":"Neuromuscul Disord"},{"key":"2600_CR49","unstructured":"Pane M, Mazzone ES, Sivo S, Fanelli L, De Sanctis R, D\u2019Amico A et al (2014) The 6 minute walk test and performance of upper limb in ambulant duchenne muscular dystrophy boys. PLoS Curr 6. ecurrents.md.a93d9904d57dcb 08936f2ea89bca6fe6"},{"issue":"5","key":"2600_CR50","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/dmcn.14361","volume":"62","author":"AG Mayhew","year":"2020","unstructured":"Mayhew AG, Coratti G, Mazzone ES, Klingels K, James M, Pane M et al (2020) Performance of Upper Limb module for Duchenne muscular dystrophy. Dev Med Child Neurol 62(5):633\u2013639. https:\/\/doi.org\/10.1111\/dmcn.14361","journal-title":"Dev Med Child Neurol"},{"issue":"4","key":"2600_CR51","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3233\/JND-221556","volume":"10","author":"M Pane","year":"2023","unstructured":"Pane M, Coratti G, Brogna C, Bovis F, D\u2019Amico A, Pegoraro E et al (2023) Longitudinal analysis of PUL 2.0 domains in Ambulant and Non-ambulant Duchenne muscular dystrophy patients: how do they change in relation to functional ability? J Neuromuscul Dis 10(4):567\u2013574. https:\/\/doi.org\/10.3233\/JND-221556","journal-title":"J Neuromuscul Dis"},{"issue":"5","key":"2600_CR52","first-page":"397","volume":"33","author":"HD Rott","year":"1985","unstructured":"Rott HD, Breimesser FH, Rodl W (1985) Imaging technics in muscular dystrophies. J Genet Hum 33(5):397\u2013403","journal-title":"J Genet Hum"},{"key":"2600_CR53","doi-asserted-by":"publisher","first-page":"131162","DOI":"10.1016\/j.ijcard.2023.131162","volume":"388","author":"TP Kerstens","year":"2023","unstructured":"Kerstens TP, van Everdingen WM, Habets J, van Dijk APJ, Helbing WA, Thijssen DHJ et al (2023) Left ventricular deformation and myocardial fibrosis in pediatric patients with Duchenne muscular dystrophy. Int J Cardiol 388:131162. https:\/\/doi.org\/10.1016\/j.ijcard.2023.131162","journal-title":"Int J Cardiol"},{"issue":"9","key":"2600_CR54","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.nmd.2018.05.011","volume":"28","author":"LC Power","year":"2018","unstructured":"Power LC, O\u2019Grady GL, Hornung TS, Jefferies C, Gusso S, Hofman PL (2018) Imaging the heart to detect cardiomyopathy in Duchenne muscular dystrophy: a review. Neuromuscul Disord 28(9):717\u2013730. https:\/\/doi.org\/10.1016\/j.nmd.2018.05.011","journal-title":"Neuromuscul Disord"},{"key":"2600_CR55","doi-asserted-by":"publisher","unstructured":"Bourke J, Turner C, Bradlow W, Chikermane A, Coats C, Fenton M et al (2022) Cardiac care of children with dystrophinopathy and females carrying DMD-gene variations. Open Heart 9(2). https:\/\/doi.org\/10.1136\/openhrt-2022-001977","DOI":"10.1136\/openhrt-2022-001977"},{"issue":"8","key":"2600_CR56","doi-asserted-by":"publisher","first-page":"e010040","DOI":"10.1161\/CIRCHEARTFAILURE.122.010040","volume":"16","author":"JH Soslow","year":"2023","unstructured":"Soslow JH, Xu M, Slaughter JC, Crum K, Kaslow JA, George-Durrett K et al (2023) Cardiovascular measures of all-cause mortality in Duchenne muscular dystrophy. Circ Heart Fail 16(8):e010040. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.122.010040","journal-title":"Circ Heart Fail"},{"issue":"9","key":"2600_CR57","doi-asserted-by":"publisher","first-page":"e897","DOI":"10.1212\/WNL.0000000000009012","volume":"94","author":"AM Barnard","year":"2020","unstructured":"Barnard AM, Willcocks RJ, Triplett WT, Forbes SC, Daniels MJ, Chakraborty S et al (2020) MR biomarkers predict clinical function in Duchenne muscular dystrophy. Neurology 94(9):e897\u2013e909. https:\/\/doi.org\/10.1212\/WNL.0000000000009012","journal-title":"Neurology"},{"issue":"8","key":"2600_CR58","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.nmd.2018.05.013","volume":"28","author":"V Straub","year":"2018","unstructured":"Straub V, Mercuri E, group DMDoms (2018) Report on the workshop: meaningful outcome measures for Duchenne muscular dystrophy, London, UK, 30\u201331 January 2017. Neuromuscul Disord 28(8):690\u2013701. https:\/\/doi.org\/10.1016\/j.nmd.2018.05.013","journal-title":"Neuromuscul Disord"},{"issue":"10","key":"2600_CR59","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/psp4.13021","volume":"12","author":"S Kim","year":"2023","unstructured":"Kim S, Willcocks RJ, Daniels MJ, Morales JF, Yoon DY, Triplett WT et al (2023) Multivariate modeling of magnetic resonance biomarkers and clinical outcome measures for Duchenne muscular dystrophy clinical trials. CPT Pharmacometrics Syst Pharmacol 12(10):1437\u20131449. https:\/\/doi.org\/10.1002\/psp4.13021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2600_CR60","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s12955-020-01511-z","volume":"18","author":"PA Powell","year":"2020","unstructured":"Powell PA, Carlton J, Woods HB, Mazzone P (2020) Measuring quality of life in Duchenne muscular dystrophy: a systematic review of the content and structural validity of commonly used instruments. Health Qual Life Outcomes 18:263. https:\/\/doi.org\/10.1186\/s12955-020-01511-z","journal-title":"Health Qual Life Outcomes"},{"issue":"8","key":"2600_CR61","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/00005650-200108000-00006","volume":"39","author":"JW Varni","year":"2001","unstructured":"Varni JW, Seid M, Kurtin PS (2001) PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care 39(8):800\u2013812. https:\/\/doi.org\/10.1097\/00005650-200108000-00006","journal-title":"Med Care"},{"issue":"1","key":"2600_CR62","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/jpepsy\/jsn067","volume":"34","author":"JGM Hendriksen","year":"2009","unstructured":"Hendriksen JGM, Poysky JT, Schrans DGM, Schouten EGW, Aldenkamp AP, Vles JSH (2009) Psychosocial adjustment in males with Duchenne muscular dystrophy: psychometric properties and clinical utility of a parent-report questionnaire. J Pediatr Psychol 34(1):69\u201378. https:\/\/doi.org\/10.1093\/jpepsy\/jsn067","journal-title":"J Pediatr Psychol"},{"issue":"9","key":"2600_CR63","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1177\/0883073810371509","volume":"25","author":"CM McDonald","year":"2010","unstructured":"McDonald CM, McDonald DA, Bagley A, Sienko Thomas S, Buckon CE, Henricson E et al (2010) Relationship between clinical outcome measures and parent proxy reports of health-related quality of life in ambulatory children with Duchenne muscular dystrophy. J Child Neurol 25(9):1130\u20131144. https:\/\/doi.org\/10.1177\/0883073810371509","journal-title":"J Child Neurol"},{"issue":"3","key":"2600_CR64","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.nmd.2016.01.003","volume":"26","author":"S Messina","year":"2016","unstructured":"Messina S, Vita GL, Sframeli M, Mondello S, Mazzone E, D\u2019Amico A et al (2016) Health-related quality of life and functional changes in DMD: a 12-month longitudinal cohort study. Neuromuscul Disord 26(3):189\u2013196. https:\/\/doi.org\/10.1016\/j.nmd.2016.01.003","journal-title":"Neuromuscul Disord"},{"issue":"10","key":"2600_CR65","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/j.jval.2021.05.016","volume":"24","author":"E Landfeldt","year":"2021","unstructured":"Landfeldt E, Iff J, Henricson E, Cooperative International Neuromuscular Research Group I (2021) Rasch Analysis of the Pediatric Quality of Life Inventory 4.0 generic core scales administered to patients with Duchenne muscular dystrophy. Value Health 24(10):1490\u20131498. https:\/\/doi.org\/10.1016\/j.jval.2021.05.016","journal-title":"Value Health"},{"issue":"1","key":"2600_CR66","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41591-018-0300-7","volume":"25","author":"EJ Topol","year":"2019","unstructured":"Topol EJ (2019) High-performance medicine: the convergence of human and artificial intelligence. Nat Med 25(1):44\u201356. https:\/\/doi.org\/10.1038\/s41591-018-0300-7","journal-title":"Nat Med"},{"issue":"7","key":"2600_CR67","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.3390\/diagnostics11071275","volume":"11","author":"B-Y Youn","year":"2021","unstructured":"Youn B-Y, Ko Y, Moon S, Lee J, Ko S-G, Kim J-Y (2021) Digital biomarkers for neuromuscular disorders: a systematic scoping review. Diagnostics (Basel) 11(7):1275. https:\/\/doi.org\/10.3390\/diagnostics11071275","journal-title":"Diagnostics (Basel)"},{"issue":"7","key":"2600_CR68","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.nmd.2019.06.003","volume":"29","author":"M Haberkamp","year":"2019","unstructured":"Haberkamp M, Moseley J, Athanasiou D, Andres-Trelles F, Elferink A, Rosa MM et al (2019) European regulators\u2019 views on a wearable-derived performance measurement of ambulation for Duchenne muscular dystrophy regulatory trials. Neuromuscul Disord 29(7):514\u2013516. https:\/\/doi.org\/10.1016\/j.nmd.2019.06.003","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"2600_CR69","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41591-022-02045-1","volume":"29","author":"V Ricotti","year":"2023","unstructured":"Ricotti V, Kadirvelu B, Selby V, Festenstein R, Mercuri E, Voit T et al (2023) Wearable full-body motion tracking of activities of daily living predicts disease trajectory in Duchenne muscular dystrophy. Nat Med 29(1):95\u2013103. https:\/\/doi.org\/10.1038\/s41591-022-02045-1","journal-title":"Nat Med"},{"issue":"4","key":"2600_CR70","doi-asserted-by":"publisher","first-page":"e0283669","DOI":"10.1371\/journal.pone.0283669","volume":"18","author":"V Ayyar Gupta","year":"2023","unstructured":"Ayyar Gupta V, Pitchforth JM, Domingos J, Ridout D, Iodice M, Rye C et al (2023) Determining minimal clinically important differences in the North Star Ambulatory Assessment (NSAA) for patients with Duchenne muscular dystrophy. PLoS ONE 18(4):e0283669. https:\/\/doi.org\/10.1371\/journal.pone.0283669","journal-title":"PLoS ONE"},{"issue":"8","key":"2600_CR71","doi-asserted-by":"publisher","first-page":"e0272858","DOI":"10.1371\/journal.pone.0272858","volume":"17","author":"F Muntoni","year":"2022","unstructured":"Muntoni F, Guglieri M, Mah JK, Wagner KR, Brandsema JF, Butterfield RJ et al (2022) Novel approaches to analysis of the North Star Ambulatory Assessment (NSAA) in Duchenne muscular dystrophy (DMD): observations from a phase 2 trial. PLoS ONE 17(8):e0272858. https:\/\/doi.org\/10.1371\/journal.pone.0272858","journal-title":"PLoS ONE"},{"key":"2600_CR72","unstructured":"project Cta The Coalition Model [ https:\/\/ctap-duchenne.org\/coalition-model\/"},{"issue":"11","key":"2600_CR73","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1111\/dmcn.12220","volume":"55","author":"AG Mayhew","year":"2013","unstructured":"Mayhew AG, Cano SJ, Scott E, Eagle M, Bushby K, Manzur A et al (2013) Detecting meaningful change using the North Star Ambulatory Assessment in Duchenne muscular dystrophy. Dev Med Child Neurol 55(11):1046\u20131052. https:\/\/doi.org\/10.1111\/dmcn.12220","journal-title":"Dev Med Child Neurol"},{"issue":"3","key":"2600_CR74","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1212\/WNL.0b013e318225ab2e","volume":"77","author":"E Mazzone","year":"2011","unstructured":"Mazzone E, Vasco G, Sormani MP, Torrente Y, Berardinelli A, Messina S et al (2011) Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study. Neurology 77(3):250\u2013256. https:\/\/doi.org\/10.1212\/WNL.0b013e318225ab2e","journal-title":"Neurology"},{"key":"2600_CR75","doi-asserted-by":"publisher","first-page":"RRN1297","DOI":"10.1371\/currents.RRN1297","volume":"4","author":"E Henricson","year":"2012","unstructured":"Henricson E, Abresch R, Han JJ, Nicorici A, Goude Keller E, Elfring G et al (2012) Percent-predicted 6-Minute Walk Distance in Duchenne muscular dystrophy to Account for Maturational influences. PLoS Curr 4:RRN1297. https:\/\/doi.org\/10.1371\/currents.RRN1297","journal-title":"PLoS Curr"},{"key":"2600_CR76","doi-asserted-by":"publisher","first-page":"13427","DOI":"10.1038\/ncomms13427","volume":"7","author":"IV Ozerov","year":"2016","unstructured":"Ozerov IV, Lezhnina KV, Izumchenko E, Artemov AV, Medintsev S, Vanhaelen Q et al (2016) In silico pathway Activation Network Decomposition Analysis (iPANDA) as a method for biomarker development. Nat Commun 7:13427. https:\/\/doi.org\/10.1038\/ncomms13427","journal-title":"Nat Commun"},{"key":"2600_CR77","doi-asserted-by":"publisher","first-page":"851491","DOI":"10.3389\/fcvm.2022.851491","volume":"9","author":"CD Vera","year":"2022","unstructured":"Vera CD, Zhang A, Pang PD, Wu JC (2022) Treating Duchenne muscular dystrophy: the Promise of Stem cells, Artificial Intelligence, and Multi-omics. Front Cardiovasc Med 9:851491. https:\/\/doi.org\/10.3389\/fcvm.2022.851491","journal-title":"Front Cardiovasc Med"},{"issue":"6","key":"2600_CR78","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/j.1469-8749.2011.03939.x","volume":"53","author":"A Mayhew","year":"2011","unstructured":"Mayhew A, Cano S, Scott E, Eagle M, Bushby K, Muntoni F et al (2011) Moving towards meaningful measurement: Rasch analysis of the North Star Ambulatory Assessment in Duchenne muscular dystrophy. Dev Med Child Neurol 53(6):535\u2013542. https:\/\/doi.org\/10.1111\/j.1469-8749.2011.03939.x","journal-title":"Dev Med Child Neurol"},{"issue":"4","key":"2600_CR79","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","volume":"10","author":"R Jaeschke","year":"1989","unstructured":"Jaeschke R, Singer J, Guyatt GH (1989) Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 10(4):407\u2013415 10.1016\/0197\u20132456(89)90005-6","journal-title":"Control Clin Trials"},{"issue":"2","key":"2600_CR80","first-page":"400","volume":"28","author":"DE Beaton","year":"2001","unstructured":"Beaton DE, Bombardier C, Katz JN, Wright JG, Wells G, Boers M et al (2001) Looking for important change\/differences in studies of responsiveness. OMERACT MCID Working Group. Outcome measures in Rheumatology. Minimal clinically important difference. J Rheumatol 28(2):400\u2013405","journal-title":"J Rheumatol"}],"updated-by":[{"DOI":"10.1007\/s13760-024-02619-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000}}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-024-02600-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-024-02600-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-024-02600-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T17:53:39Z","timestamp":1741024419000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-024-02600-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["2600"],"URL":"https:\/\/doi.org\/10.1007\/s13760-024-02600-2","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s13760-024-02619-5","asserted-by":"object"}]},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,31]]},"assertion":[{"value":"23 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s13760-024-02619-5","URL":"https:\/\/doi.org\/10.1007\/s13760-024-02619-5","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MP reported personal fees from Roche, PTC, Pfizer outside the submitted work. SB and FG are Pfizer employees. LB and MP were paid consultants to Pfizer in connection with the development of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}